Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.
Rare-disease biopharma with several approved drugs (Crysvita, Dojolvi, Mepsevii) and a broad gene-therapy pipeline.
Each medicine serves very few patients and is sold at a high price per patient, so a handful of products carry the company. Crysvita, the largest, is shared with Kyowa Kirin. Gene therapies under development are funded by that income and by share sales.
Moat: narrow (IP / patents, regulatory licence). Multiple orphan-drug approvals in ultra-rare diseases with few or no competitors.
Headquarters: Novato, California, US · Founded: 2010 · Employees: 1,371
Size Ultragenyx Pharmaceutical (RARE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1845th largest of 3,085 United States companies the cockpit tracks. Shares closed at $17.73 on 18 Nov 2026.
Performance Over six months the shares fell 24.1%, against -7.3% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 15.8% over the last twelve months (peer median +4.2%); the operating margin is -64.1% (peer median 10.0%).
Valuation It trades at 9.6× forward earnings against a peer median of 19.7× (cheapest of 18).
Capital Return on invested capital runs 73.6 points below its cost of capital (6.4% WACC).
Short interest Short interest is 23.2% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $730M | $673M | $560M | $434M | $363M |
| Revenue growth | — | +20% | +29% | +20% | — |
| Gross profit | $571M | $537M | $453M | $367M | $320M |
| EBITDA | -$434M | -$500M | -$500M | -$543M | -$631M |
| Net income | -$524M | -$575M | -$569M | -$607M | -$707M |
| Free cash flow | -$442M | -$472M | -$422M | -$519M | -$497M |
| Capital expenditure | $9.94M | $21.0M | $20.0M | $46.8M | $146M |
| Total debt | $1.19B | $1.25B | $910M | $935M | $907M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical RARE | $1.81B | -24% | +16% | -64% | 9.6× | n/a |
| BioMarin Pharmaceutical BMRN | $11.9B | +22% | +20% | 19% | 11.2× | 8.2% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| Ionis Pharmaceuticals IONS | $4.56B | -64% | -1% | -59% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RARE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.7% | -1.0% | 3rd highest of 21 |
| 6-month return | -24.1% | -7.3% | 6th lowest of 21 |
| Distance from 52-week high | -55.5% | -32.8% | 2nd lowest of 21 |
| Revenue growth (TTM) | +15.8% | +4.2% | 5th highest of 21 |
| Operating margin | -64.1% | 10.0% | 3rd lowest of 21 |
| Forward P/E | 9.6× | 19.7× | cheapest of 18 |
| ROIC minus cost of capital | -73.6 pp | +2.4 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical RARE | United States | $1.81B | -24% | +16% | -64% | 9.6× | n/a | n/a |
| Qingdao Baheal Medical 301015.SZ | China | $1.81B | +2% | -6% | 8% | 21.0× | 10.1% | +5.0% |
| Shenzhen Hepalink Pharmaceutical 002399.SZ | China | $1.80B | -12% | -6% | 8% | 25.8× | -0.7% | +0.5% |
| Zymeworks ZYME | United States | $1.81B | +5% | +98% | 17% | 160.4× | n/a | n/a |
| China National Accord Medicines 000028.SZ | China | $1.81B | -3% | 0% | 2% | 10.8× | -9.5% | +4.2% |
| United Laboratories International 3933.HK | Hong Kong | $1.80B | -20% | -13% | 5% | 13.0× | 1.2% | +7.8% |
| Guobang Pharma 605507.SS | China | $1.82B | -6% | +3% | 12% | 15.7× | -6.0% | +7.4% |
| Eton Pharmaceuticals ETON | United States | $1.79B | +226% | +101% | 29% | 24.6× | 21.9% | +359.6% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.83B | -25% | +17% | 33% | 13.0× | 5.4% | +29.1% |
| Harbin Pharmaceutical 600664.SS | China | $1.78B | +32% | +2% | 5% | 19.7× | -5.3% | +8.2% |
| Agios Pharmaceuticals AGIO | United States | $1.78B | +4% | +214% | -298% | n/a | n/a | n/a |
| Dermapharm DMP.DE | Germany | $1.85B | -29% | +2% | 21% | 13.2× | -3.4% | +8.0% |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $1.85B | -38% | +5% | -18% | n/a | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.87B | +7% | +14% | 2% | 96.3× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.87B | -8% | +13% | 27% | 12.5× | -1.2% | +16.7% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| NATCO Pharma NATCOPHARM.NS | India | $1.73B | -27% | -30% | 17% | 19.1× | 20.5% | +19.0% |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| BrightGene Bio-Medical Technology 688166.SS | China | $1.71B | -57% | +14% | 7% | 74.9× | 35.3% | +9.2% |
| Maze Therapeutics MAZE | United States | $1.71B | +27% | -100% | -821% | n/a | n/a | n/a |